A 52-year-old woman presents with a 6-week history of symmetrical polyarthritis affecting her hands, wrists, and knees. Morning stiffness lasts 2 hours. On examination, she has soft tissue swelling over the PIP and MCP joints bilaterally. Laboratory investigations show: ESR 68 mm/hr, CRP 45 mg/L, RF 280 IU/mL (positive), anti-CCP antibodies 95 U/mL (positive). Plain radiographs of hands show periarticular osteopenia but no erosions. What is the most appropriate next step in management?
A. Refer to rheumatology for biologic DMARD therapy (TNF inhibitor) as first-line treatment
B. Perform arthrocentesis and synovial fluid analysis to confirm diagnosis
C. Initiate a conventional synthetic DMARD (e.g., methotrexate) along with a short course of prednisolone and NSAIDs
D. Start prednisolone 20 mg daily and review in 2 weeks
Explanation
Clinical Context
This patient presents with early, seropositive (RF and anti-CCP positive), active rheumatoid arthritis (RA) with no radiographic erosions yet—a window of opportunity for disease-modifying therapy.
Rationale for Correct Answer
Key Point
Early, aggressive DMARD initiation within 3 months of symptom onset is the standard of care in RA and significantly improves long-term outcomes and prevents joint damage.
The correct next step is to start a conventional synthetic DMARD (csDMARD) such as methotrexate, combined with:
Short-term corticosteroids (prednisolone 10–15 mg daily, tapered over 8–12 weeks) for rapid anti-inflammatory effect
NSAIDs for symptomatic relief
This "treat-to-target" approach, aiming for remission or low disease activity, is endorsed by ACR/EULAR guidelines and is the standard first-line strategy in early RA.
Why Not the Other Options
High-YieldNEET PG
Monotherapy with corticosteroids alone (option 1) is inadequate—steroids do not modify disease progression and are used only as a bridge therapy alongside DMARDs.
Clinical Pearl
Arthrocentesis (option 3) is not needed to confirm RA diagnosis when serology (RF, anti-CCP) and clinical presentation are already diagnostic. It may be used to exclude other conditions (infection, crystal arthropathy) if diagnosis is unclear, but it is not the next step here.
Biologic therapy (option 4) is reserved for:
Inadequate response to csDMARD monotherapy or combination therapy
High disease activity despite conventional therapy
Poor prognostic factors (high RF/anti-CCP, early erosions)
It is not first-line in early RA without prior csDMARD trial.
